Domain Registration

Coronavirus Vaccine: Moderna and Pfizer Reveal Secret Blueprints Trials

  • September 18, 2020

“I want to acknowledge a good deed done,” said Peter Doshi, who is on the faculty at the University of Maryland School of Pharmacy in Baltimore and an editor with The BMJ, a medical journal. He previously requested the plans from Moderna and Pfizer. “They have opened up, for the first time, the ability for researchers not involved in the trial to form their own independent judgment about the design of this study.”

Until now, none of the nine companies that are testing vaccines in large clinical trials had released this level of detail.

Moderna, AstraZeneca and Pfizer, which is collaborating with the German company BioNTech, are among the front-runners in the global race to produce a vaccine to fight the pandemic.

A spokeswoman for AstraZeneca said the company intended to publish its protocol shortly. Novavax, which is expected to start a large, advanced clinical trial later this year, also did not comment. Johnson Johnson, which has said it plans to begin a large trial this month, said it would have “more information to share” when the trial starts.

AstraZeneca’s trial was stopped temporarily because of serious illness in a participant. It has resumed in Britain and Brazil, but not in the United States.

Earlier studies of both vaccines in small numbers of people found that after the second shot, they developed so-called neutralizing antibodies, which can inactivate the virus in lab tests. The vaccines also produced a favorable response involving T-cells, another part of the immune system.

Dr. Tal Zaks, chief medical officer for Moderna, the first coronavirus vaccine maker to release its detailed plan, said pharmaceutical companies were usually reluctant to do so, for competitive reasons.

Article source: https://www.nytimes.com/2020/09/17/health/covid-moderna-vaccine.html

Related News

Search

Find best hotel offers